Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822416 · ClinicalTrials.gov registry record · Phase 2
Treating Smokers With Mental Illness
A Phase 2 study of Schizophrenia and Major Depressive Disorder, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT03822416 is a Phase 2 study of Schizophrenia and Major Depressive Disorder that has completed, run by University of Minnesota. The registered enrollment target is 38 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03822416, a Phase 2 study of Schizophrenia and Major Depressive Disorder, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a smoking cessation study that will enroll smokers who have been diagnosed with a severe mental illness. The study will use a combination of intensive tobacco treatment counseling and nicotine replacement therapy to assist smokers in cutting back on and quitting smoking over the course of six months.
Conditions Studied
Interventions
- DRUG Nicotine patch
- BEHAVIORAL Therapy
- OTHER Information
- DRUG Nicotine lozenge
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2020-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03822416
The ClinicalTrials.gov registry entry for NCT03822416 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (83% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Schizophrenia appearing as the primary indexed condition, and to 4 interventions - of which Nicotine patch is the first listed.
NCT03822416 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03822416 about?
NCT03822416 is a clinical study titled "Treating Smokers With Mental Illness". This is a smoking cessation study that will enroll smokers who have been diagnosed with a severe mental illness. The study will use a combination of intensive tobacco treatment counseling and nicotine replacement therapy to assist smokers in cutting back on and quitting smoking over the course of si...
What is the current status of trial NCT03822416?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2019-03-01. Estimated completion is 2020-05-04.
What conditions does trial NCT03822416 study?
This clinical trial studies the following conditions: Schizophrenia, Major Depressive Disorder, Smoking Cessation, Cigarette Smoking, Psychotic Disorders.
What interventions are being tested in trial NCT03822416?
The interventions under investigation include: Nicotine patch (DRUG), Therapy (BEHAVIORAL), Information (OTHER), Nicotine lozenge (DRUG).
Who is sponsoring clinical trial NCT03822416?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03822416 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.